

**Tab. 1 Supp** Baseline characteristics of the cohort at enzyme replacement therapy initiation.

(Abbreviations: LVH: Left Ventricular Hypertrophy; BP: Blood Pressure).

			All (n=60)	No baseline LVH (n=38)	Baseline LVH (n=22)	p
Clinical						
Age	Years		35 [23-48]	27 [21-36]	50 [44-54]	<0.001
Men	n (%)		40 (66%)	22 (56 %)	18 (82%)	0.03
Systolic BP (n=31)	mmHg		124 ± 13	123 ± 10	127 ± 16	0.34
Diastolic BP (n=31)	mmHg		77 ± 9	76 ± 7	79 ± 13	0.37
Arterial hypertension	n (%)		10 (17%)	3 (8%)	7 (31%)	0.03
Echocardiography						
Septal thickness	mm		11.6 ± 4.2	9.1 ± 2.1	16.1 ± 3.0	<0.001
Relative wall thickness	%		46 ± 19	66 ± 16	36 ± 8	<0.001
LV diastolic diameter	mm		45.9 ± 4.7	47.1 ± 5.4	43.8 ± 4.4	0.008
LV mass index	kg/m <sup>2</sup>		105 ± 43	79 ± 18	150 ± 38	<0.001
Left atrial diameter	mm		33 ± 6	31 ± 6	36 ± 6	0.002
Mitral annulus e' velocity	cm/s		13.3 ± 8.7	13.6 ± 4.0	12.7 ± 14.0	0.69
Mitral E/e' ratio			7.8 ± 5.0	6.7 ± 2.0	9.9 ± 7.8	0.02

**Fig. 1 Supp.** Evolution of Indexed LV mass during four echocardiographies in the follow-up among progressors patients under Enzyme Replacement Therapy.

(Abbreviations: Pt : Patient).

